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Background: TANK-binding kinase (TBK1) is a non-canonical IκB kinase (IKK) involved in the regulation of type I
interferons and of NF-κB signal transduction. It is activated by viral infections and inflammatory mediators and
has therefore been associated with viral diseases, obesity, and rheumatoid arthritis. Its role in pain has not been
investigated so far. Due to the important roles of NF-κB, classical IκB Kinases and the IKK-related kinase, IKKε, in
inflammatory nociception, we hypothesized that TBK1, which is suggested to form a complex with IKKε under
certain conditions, might also alter the inflammatory nociceptive response.
Methods: We investigated TBK1 expression and regulation in “pain-relevant” tissues of C57BL/6 mice by
immunofluorescence, quantitative PCR, and Western blot analysis. Furthermore, nociceptive responses and
the underlying signal transduction pathways were assessed using TBK1−/− mice in two models of inflammatory
nociception.
Results: Our data show that TBK1 is expressed and regulated in the spinal cord after peripheral nociceptive
stimulation and that a deletion of TBK1 alleviated the inflammatory hyperalgesia in mice while motor function and acute
nociception were not altered. TBK1-mediated effects are at least partially mediated by regulation of NF-κB dependent
COX-2 induction but also by alteration of expression of c-fos via modulation of MAP kinases as shown in the spinal cord
of mice and in cell culture experiments.
Conclusion: We suggest that TBK1 exerts pronociceptive effects in inflammatory nociception which are due to both
modulation of NF-κB dependent genes and regulation of MAPKs and c-fos. Inhibition of TBK1 might therefore constitute
a novel effective tool for analgesic therapy.
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TANK-binding kinase 1 (TBK1, NAK1, T2K) constitutes an
IκB kinase (IKK)-related kinase which has been associated
with interferon regulatory factor (IRF)- and nuclear factor
(NF)-κB-activation [1]. In this context, it is involved in in-
nate immune defense and its dysregulation has been de-
scribed in the context of several diseases, particularly
inflammatory disorders and cancer. So far, it is not clear
which of the TBK1-driven pathways is functionally active in* Correspondence: e.niederberger@em.uni-frankfurt.de
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unless otherwise stated.different diseases. Several publications suggest that TBK1 is
able to act in context with its potential binding partner IκB
kinase epsilon (IKKε) [2–4]. On the other hand, it is pro-
posed to be an independent kinase [5, 6], a suggestion that
is favored by constitutive TBK1 expression in many cells
while IKKε must be induced by a variety of stimuli in most
cells. To date, it appears that pain, inflammation, and can-
cer are associated with IKKε- or TBK1-specific NF-κB
pathway activation while IRFs and the IFN pathways are in-
volved in pathologies such as rheumatic diseases [7]. The
classical NF-κB activation cascade has frequently been asso-
ciated with the development of pathophysiological pain
(reviewed in [8]). Depletion of NF-κB p50 as well asThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Primer sequences for genotyping
Primers
TBK1 wild 5′- CTAATGGTTGTAGTCAGGGTCTCCTGC -3′
TBK1 extra 5′- TGCGTTCCTGTCCTGACCGTGATTGTG -3′
TBK1 neo 5′- ATCGCCTTCTATCGCCTTCTTGACGAG -3′
TNFRSense1 5′- AGATGGAGAAGGGCAGTTAG -3′
AntiS1 5′- ATACCAGGGTTTGAGCTCAG -3′
AntiS2 5′- TACTTTGTTAAGAAGGGTGAGA -3′
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duced nociceptive responses due to a decreased expres-
sion of NF-κB-regulated genes [9–12]. We recently
showed that IKKε affects inflammatory nociception also
by modulation of NF-κB rather than IRF activity. Dele-
tion of IKKε in mice reduced the nociceptive behavior
in inflammatory models associated with a loss of
inflammation-evoked NF-κB activation and a decreased
induction of NF-κB dependent proinflammatory genes
while IRF-3 was not altered. Knock-down of IKKε by
siRNA indicated that impaired phosphorylation of p65
serine 536 might be the underlying molecular mechan-
ism for the NF-κB inhibition [13].
The role of TBK1 in nociception has not been investi-
gated so far although several data hint at important
TBK1 functions, particularly in inflammatory processes.
TBK1 modulation has been associated with regulation of
inflammatory mediators such as IL-6, TNF-α, or IFN-β
[14, 15], and TBK1-deficient cells show strong defects in
IFN induction [16]. TBK1-depleted fibroblast-like syno-
viocytes revealed reduced capacity for IRF-3-mediated
induction of IFN-β and IP-10, suggesting that, particu-
larly, TBK1 is involved in the pathogenesis of rheuma-
toid arthritis [17]. Furthermore, TBK1 is involved in
insulin receptor signaling and might therefore form a
link between inflammation and insulin resistance/dia-
betes [18]. In this study, we investigated its expression,
regulation, and function in the nervous system during
inflammatory nociception in two mouse models of in-
flammatory hyperalgesia to determine the impact of




C57BL/6 mice were obtained from Harlan Winkelmann,
Germany at the age of 6–8 weeks. TBK1−/−/TNFR−/−-mice
were kindly provided by Prof. Shizuo Akira, Japan. For
TBK1 deletion, a 1.5-kbp fragment in exon 9 of the murine
TBK1 gene was replaced with a neomycin-resistant
gene cassette. Mice heterozygous for TBK1 remain
alive and healthy. However, TBK1−/− mice have been
shown to die around embryonic day 14.5 (E14.5) [16].
Therefore, mice have to be bred on a TNF-receptor
knock-out (TNFR−/−) background [19] which prevents
premature death [20]. TBK1−/−/TNFR−/− mice were
crossed with TBK1+/+/TNFR−/− mice and heterozygous
offspring were then mated to generate TBK1+/+/TNFR−/−
and TBK1−/−/TNFR−/− littermates. Backcrossing with
C57BL/6 wild type mice was performed to generate
TBK1+/+/TNFR+/+ littermates. Genotyping was per-
formed using the primers in Table 1.
For experiments, we used 2–3-month-old littermate
mice. Animals had free access to food and water and weremaintained in climate- and light-controlled rooms (24 ±
0.5 °C, 12/12 dark/light cycle). In all experiments, the eth-
ical guidelines for investigations in conscious animals were
obeyed and the procedures were approved by the local
Ethics Committee for Animal Research (F95/53). All efforts
were made to minimize animal suffering and to reduce the
number of animals used. All behavioral experiments were
assessed by a blinded observer in a dedicated room with
restricted sound level and activity.Western blot analysis
For Western blot analysis, mice were injected with either
formalin or zymosan A into the hind paws. Lumbar
spinal cords (L4-L6) were dissected out at the indicated
time points. Tissues were homogenized in PhosphoSafe
Extraction Buffer (Merck, Darmstadt, Germany) with
protease inhibitor mixture (1 mM Pefabloc SC Alexis
Biochemicals, Lausen, Switzerland) immediately after
preparation. To remove cellular debris, extracts were
centrifuged at 16.800 × g for 1 h at 4 °C. The superna-
tants were stored at –80 °C. Proteins from tissue homog-
enates (15–30 μg) were separated electrophoretically by
10 % SDS-PAGE and then transferred onto nitrocellu-
lose membranes by wet-blotting. To confirm equal load-
ing all blots were stained with Ponceau S red solution.
Membranes were blocked for 60 min at room temperature
in Odyssey blocking reagent (LI-COR Biosciences, Bad
Homburg, Germany) diluted 1:2 in 0.1 M PBS, pH 7.4.
Then the blots were incubated overnight at 4 °C with pri-
mary antibody against TBK1 (84 kDa), p42 (42 kDa), p-
p42 (42 kDa), p44 (44 kDa), p-p44 (44 kDa), JNK
(46 kDa), p-JNK (46 kDa), SAPK (54 kDa), p-SAPK
(54 kDa), p-p65(Ser536) (65 kDa) (all 1:250, Cell Signaling
Technology, Boston, USA) in blocking buffer. After
washing three times with 0.1 % Tween 20 in 0.1 M
PBS, the blots were incubated for 60 min with an
IRDye 800- or IRDye 700-conjugated secondary anti-
body (1:5000 in blocking buffer). After rinsing in 0.1 %
Tween 20 in 0.1 M PBS, protein-antibody complexes
were detected with the Odyssey Infrared Imaging System
(LI-COR, Bad Homburg, Germany). β-Actin (37 kDa),
(1:1200, Sigma) or Hsp90 (90 kDa), (1:500, BD Bioscience)
was used as loading control. Densitometric analysis of the
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COR, Bad Homburg, Germany).
Real-time PCR (Taqman)
RNA was prepared from the lumbar spinal cords and
dorsal root ganglia (DRGs) (L4-L6) using TRI reagent
according to the standard procedure [13]. Two hundred
nanogram of total RNA was used for the reverse transcrip-
tion which was performed with Random and Oligo-dT
Primers (2:1 ratio) in a Verso cDNA Synthesis Kit (Thermo
Scientific, Darmstadt, Germany). Twenty nanogram RNA
equivalent was subjected to real-time PCR in an Applied
Biosystems sequence detection system AB7500 using the
FastStart Universal SYBR Green Master (Rox) System
(Roche Diagnostics, Mannheim, Germany). Expression of
TBK1, COX-2, iNOS, MMP-9, c-fos, and Akt1 mRNA was
assessed related to GAPDH mRNA. The following gene-
specific primers were used:
TBK1 FW5′-GAG CCG GGA ACA ACT CAA TA-3′














GAPDHFW5′-CAATGT GTC CGT CGT GGATCT-3′
RV5′-GTC CTC AGT GTA GCC CAA GAT G-3′
The cycle number at which the fluorescence signal
crosses a defined threshold (Ct-value) is proportional to
the number of RNA copies present at the start of the
PCR. The threshold cycle number for the specific mRNA
was standardized by subtracting the Ct-value of GAPDH
from the Ct-value of gene-specific amplifications of the
same sample. Relative quantitative level of samples was
determined by standard 2(-ΔΔCt) calculations and expressed
as fold-change in a single reference control sample (un-
treated control mice of either genotype).
Immunofluorescence
Mice were perfused intracardially with 0.9 % saline
followed by 4 % paraformaldehyde in 0.1 M phosphate-
buffered saline (PBS), pH 7.4, under deep ketamine/
xylazine anesthesia. Lumbar spinal cords (L4-L6) were
dissected out, post-fixed in 4 % PFA in 0.1 M PBS (pH 7.4),cryoprotected in 20 % sucrose in 0.1 M PBS overnight at
4 °C and then embedded in Tissue-Tek O.C.T. Compound
(Sakura Finetek Europe B.V., Alphen aan den Rijn,
Netherlands) frozen on dry ice. Cryostat sections were cut
at a thickness of 16 μm and stored at −80 °C. For immuno-
fluorescence, slices were permeabilized for 15 min with
0.1 M PBS containing 0.1 % Triton-X 100. The sections
were then blocked in 3 % BSA in 0.1 M PBS for 1 h to re-
duce non-specific binding. After rinsing in 0.1 M PBS, sec-
tions were incubated with TBK1 antibody (1:500, Acris)
and for co-immunofluorescence with mouse anti-neuronal
nuclei (NeuN, 1:1000, Sigma Aldrich), mouse anti-GFAP
(1:1000, Chemicon), or CD11b (1:500). Antibodies were
dissolved in 0.1 % Tween 20 in 0.1 M PBS and incubated
at 4 °C overnight. After rinsing in 0.1 M PBS, sections were
incubated for 2 h at room temperature with Alexa Flour
488- or Cy3-conjugated secondary antibodies dissolved in
0.1 % Tween 20 in 0.1 M PBS, rinsed again in 0.1 M PBS
and coverslipped with Fluoromount G. Images were cap-
tured using an inverted fluorescence microscope (Axio
Observer.Z1; Zeiss, Germany) equipped with a mono-
chrome CCD camera and AxioVision software (Zeiss,
Germany).
Transcription factor analysis
Nuclear extracts from the spinal cord or cell culture were
prepared using a commercially available Nuclear Extract
Kit following the manufacturer’s instructions (Active Motif,
Rixensart, Belgium). These nuclear extracts were then
subjected to TransAMTM NF-κB p65, c-fos, and IRF-3
transcription factor ELISAs (Active Motif). Five microgram
nuclear protein was allowed to bind to an oligonucleotide-
coated plate. NF-κB p65, c-fos, or IRF-3 was detected by
incubation with specific primary antibodies and HRP-
conjugated secondary antibody. The colorimetric readout
was measured photometrically at 450 nm and is propor-
tional to transcription factor activity.
Behavioral testing
Littermates were used in all behavioral tests. Animals
were habituated to the experimental room and were in-
vestigated by observers blinded for the genotype of the
animals. Genotyping was done as described above.
Rotarod test
Motor coordination was assessed with a Rotarod Treadmill
for mice (Ugo Basile, Comerio, Italy) at a constant rotating
speed of 32 rpm. All mice had five training sessions before
the day of the experiment. The fall-off latency was averaged
from five tests. The cut-off time was 90 s.
Mechanical sensitivity
Paw withdrawal latency in response to mechanical stimula-
tion was assessed with an automated testing device
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surface of the paw with increasing force until the paw is
withdrawn (Dynamic Plantar Aesthesiometer, Ugo Basile,
Varese, Italy). The maximum force was set at 5 g to prevent
tissue damage and the ramp speed was 0.5 g/s. The cut-off
time was 20 s. Mice were placed in test cages with a metal
grid bottom. After 1-h accommodation time, the paw with-
drawal latency was measured. The mean of 4–6 consecutive
trials at each time point were used for further analysis.
Hot-plate test
Animals were placed into a Plexiglas cylinder on a
heated plate maintained at 52.0 ± 0.2 °C (Ugo Basile),
and the latency to jump, shake/flutter a hind paw, or
licking the front paws was recorded. Each animal was
tested only once since repeated testing in this assay leads
to latency changes [21]. The cut-off time was 30 s.
Formalin test
The formalin test was performed as described [22]. Mice
were placed on a table top within a Plexiglas cylinder
and were allowed to habituate for 30 min. Twenty mi-
croliters of a 5 % formaldehyde solution (formalin) was
injected subcutaneously into the dorsal surface of the
left hind paw. The time spent licking the formalin-
injected paw was recorded at 5 min intervals up to
45 min, starting right after formalin injection. Two
hours after, formalin injection animals were deeply anes-
thetized with isoflurane and then killed by cardiac punc-
ture. Lumbar spinal cords and DRGs (L4-L6) were
dissected out and immediately frozen in liquid nitrogen
and stored at −80 °C until further preparation.
Zymosan A-induced paw inflammation
Paw withdrawal latency in response to mechanical
stimulation was assessed as described above. Mice were
placed in test cages with a metal grid bottom. After 1 h,
baseline paw withdrawal latencies were measured. On
the next day, hind paw inflammation was induced by
subcutaneous injection of 20 μl of a 10 mg/ml zymosan
A (Sigma-Aldrich, Munich, Germany) suspension in
phosphate-buffered saline (0.1 M, pH 7.4) into the mid
plantar region of the left hind paw [23]. The mean of
four consecutive trials with 10 s intervals was deter-
mined hourly up to 8 h after zymosan A injection and
then again after 24 and 48 h. At the end of the observa-
tion period (48 h after zymosan A injection), animals
were deeply anesthetized with isoflurane and then killed
by cardiac puncture. Lumbar spinal cords and DRGs
(L4-L6) were dissected out and immediately frozen in li-
quid nitrogen and stored at −80 °C until further prepar-
ation. Ipsi- and contralateral paws were detached at the
ankle. The paw volume was determined by weighing the
paws.Cell culture
RAW264.7 mouse macrophages were cultured and incu-
bated in RPMI 1640 medium containing 10 % FCS and 1 %
penicillin/streptomycin. Cells were stably transduced
with either TBK1-specific shRNA (GIPZ-system, Thermo
Scientific, Germany) or negative control virus (NC) and
cultivated under puromycin selection. Permanent expres-
sion of shRNA resulted in 80 % reduction of the TBK1
protein level, which remained stable throughout the whole
incubation period (Additional file 1: Figure S6 A). Bone
marrow derived macrophages (BMM) were generated
from TNFR−/− and TBK1−/−/TNFR−/− mice. Muscle tissue
was removed from the hind legs, and the bones were cut
directly beyond and above the joints. The bones were
placed into a perforated 0.2 ml tube, which was inserted
into a 1.5 ml reaction tube. After centrifugation at
16.800 × g for 15 s, the bone marrow was resuspended in
RPMI 1640 medium supplemented with 10 % FCS, 1 %
Pen/Strep, and 20 ng/ml recombinant murine macrophage
colony stimulating factor (M-CSF, Peprotech, Hamburg,
Germany). Cells were seeded in six well plates and culti-
vated and differentiated for 7 days before stimulation.
RAW264.7 and BMM were stimulated with 10 μg/ml
lipopolysaccharide (LPS) for the indicated time points.
Protein was isolated using Phophosafe/Pefabloc (Merck/
Novagen, Darmstadt, Germany/Alexis Biochemicals,
Lörrach, Germany) according to manufacturer’s instruction.
Data analysis
Statistical evaluation was done with Graph Pad Prism
5.0 for Windows. Data are presented as mean ± SEM.
Data were either compared by univariate analysis of vari-
ance (ANOVA) with subsequent t tests employing a
Bonferroni α-correction for multiple comparisons or by
student’s t test. For analysis of inflammatory hyperalgesia
in the zymosan A-induced paw inflammation, paw with-
drawal latencies in response to mechanical stimulation
were expressed as the relative difference between the zy-
mosan A-treated left and the untreated right hind paw
calculated as ΔPWL = (left-right) / right × 100 (mean ±
SEM). For analysis of inflammatory hyperalgesia in the
zymosan A-induced paw inflammation and the formalin
test, repeated measures ANOVA was performed. For all
tests, a probability value P < 0.05 was considered as sta-
tistically significant.
Results
Expression and regulation of TBK1 in the spinal cord and
the DRGs
Constitutive TBK1 expression in the spinal cord was
detected by immunofluorescence (Fig. 1). The specifi-
city of the TBK1 antibody was confirmed with tissues
from TBK1−/−/TNFR−/− mice, which showed no signal












Fig. 1 TBK1 expression in the dorsal spinal cord. Representative co-immunofluorescence showing TBK1 protein expression in the dorsal horn of
spinal cord in combination with cell markers for (a) astrocytes (GFAP), (b) neurons (NeuN), and (c) microglia (CD11b). TBK1 was stained with Cy3
(red), cell markers with Alexa Fluor 488 (green). The three images show from left to right: TBK1 alone, cell marker alone, and merged (representative result
from three independent experiments). The arrows indicate double-labeled cells. Scale Bar, 10 μm
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astrocytes revealed TBK1 localisation in NeuN-positive
neurons and some GFAP-positive astrocytes. CD11b-
positive microglial cells showed no co-staining with TBK1
indicating that it is not expressed in this cell type under
naïve conditions (Fig. 1). Accordingly, we found low levels
of basal TBK1 expression in primary microglia and astro-
cytes, which however were upregulated upon inflamma-
tory stimulation with a cytokine mix (Additional file 3:
Figure S2). To gain an impression whether TBK1 expres-
sion in the spinal cord is due to localization in neurons of
the terminals of primary nociceptive afferents, immuno-
fluorescence images from DRG slides were prepared
additionally. TBK1 expression was detectable in small
non-myelinated nociceptive neurons and large myelinated
non-nociceptive neurons of the DRGs, as assessed by
co-staining with IB4 and Neurofilament 200, respect-
ively (Additional file 4: Figure S3), indicating its role innociceptive transmission as well as general functions in
sensory perception in the periphery. Potential regula-
tion of spinal TBK1 during nociception was assessed in
two different inflammatory models in mice: the forma-
lin test which reflects short time tonic nociception as-
sociated with mechanisms of central sensitization and
the zymosan A-induced paw inflammation model
which leads to the formation of paw edema and in-
creased sensitivity to nociceptive stimuli that lasts for
several days. In both models, we observed an increase
in TBK1 mRNA and protein levels in the spinal cord
after peripheral noxious stimulation (Fig. 2) suggesting
that TBK1 is a modulator of inflammatory nociception
and sensitization towards ongoing nociceptive input. In
contrast, no TBK1 regulation after inflammatory nocicep-
tive stimulation could be observed in DRGs indicating
its main function in nociceptive processing in the cen-
tral nervous system (Additional file 4: Figure S3).
** * *
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Fig. 2 TBK1 regulation in the spinal cord after peripheral inflammatory stimulation. Time course of the TBK1 mRNA and protein expression in the
lumbar spinal cord after peripheral injection of zymosan A (a, c) and formalin (b, d), respectively (n= 4 mice/group). The Western blots (c, d) show one
representative blot; the diagrams depict the densitometric analysis of all blots (mean ± S.E.M). Univariate ANOVA with Bonferroni post-hoc
analysis *P < 0.05, **P < 0.01, and ***P < 0.001
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in inflammatory models
Genetically modified mice were used to further evaluate
TBK1 function in nociceptive processing. Before starting
nociceptive tests, the Rotarod Test was performed to
assess intact motoric coordination of TBK1−/−/TNFR−/−
and TNFR−/− mice, which is an important prerequisite
for proper behavioral nociceptive testing. Neither
TBK1−/−/TNFR−/− nor TNFR−/− mice showed any dif-
ferences in their ability to balance on the rotating rod
and remained there until the cut-off time of 90 s indi-
cating that the genetic modification does not impair
their motor functions. Hot-plate and Dynamic Plantar
tests were applied to assess the impact of the genetic
modifications on acute thermal and mechanical noci-
ception, respectively. The results of both tests showed
that there were no significant differences between
TBK1−/−/TNFR−/− and TNFR−/− mice indicating that
the physiologically important immediate response toacute noxious thermal and mechanical stimulation is
unaffected in the knock-out mice (mean ± SEM; Hot
Plate: TNFR−/− 14.7 ± 1.1; TBK1−/−/TNFR−/− 19.4 ±
2.0 (P = 0.101); Dynamic Plantar: TNFR−/− 7.7 ± 0.6;
TBK1−/−/TNFR−/− 7.6 ± 0.6). Due to the homology of
TBK1 with other IκB kinases and a potential compen-
satory regulation of similar proteins in response to sys-
temic knock-out of genes, we determined the protein
levels of IKKα, IKKβ, and IKKε in spinal cord protein
extracts of TBK1−/−/TNFR−/−, TNFR−/−, and wild type
mice. The results of the Western blot analysis showed
equal protein expression for all kinases in all genotypes
tested suggesting that these proteins were not com-
pensatory regulated in TBK1 knock-out mice (data not
shown).
In the inflammatory nociceptive models, wild type
littermates showed typical nociceptive responses. After
injection of zymosan A, a strong decrease in paw with-
drawal latencies towards mechanical stimulation was
Möser et al. Journal of Neuroinflammation  (2015) 12:100 Page 7 of 13observed which lasted until the end of the experiment at
48 h (Fig. 3a). This effect was already reduced in TNFR−/−
animals and further alleviated in TBK1−/−/TNFR−/−
mice in the period from 3 h up to 48 h after zymosan A
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Fig. 3 Inflammatory hyperalgesia in TNFR−/− and TBK1−/−/TNFR−/− mice. a
triangle), TNFR−/− (dark grey square), and TBK1−/−/TNFR−/− (light grey circle) m
The diagram shows the delta paw withdrawal latencies (ΔPWL) in respons
Aesthesiometer (n = 6 mice/group), repeated measure ANOVA with Bo
panel: comparison of the area under the paw withdrawal latency versus tim
and TBK1−/−/TNFR−/− (light grey column) mice 3 to 48 h after zymosan A inje
significant mean difference between the respective genotypes. Lower rig
TNFR−/− (dark grey column), and TBK1−/−/TNFR−/− (light grey column) mice 4
behavior in wild type (black triangle), TNFR−/− (dark grey square), and TBK1−/
formalin (5 %, 20 μl) into the hind paw. Formalin was injected at time ‘0’, an
intervals for 45 min. Right panel: statistical analysis of phase I (0–5 min
TNFR−/− (dark grey column), and TBK1−/−/TNFR−/− (light grey column).
significant mean difference between the respective genotypesTBK1−/−/TNFR−/− mice at 48 h (repeated measures
ANOVA, *P < 0.05 (TNFR−/−) and **P < 0.01 (TBK1−/−/
TNFR−/−). To investigate the impact of TBK1 on paw
inflammation, the zymosan A-injected paws were


































































Left panel: time course of mechanical hyperalgesia in wild type (black
ice after injection of 10 mg/ml (20 μl) zymosan A into a hind paw.
e to mechanical stimulation as assessed with a Dynamic Plantar
nferroni post-hoc analysis, *P < 0.05 and **P < 0.01. Upper right
e curve between wild type (black column), TNFR−/− (dark grey column),
ction. Univariate ANOVA with Bonferroni post-hoc analysis #P<0.05
ht panel: determination of the paw weight of wild type (black column),
8 h after zymosan A injection. b Left panel: time course of the licking
−/TNFR−/− (light grey circle) mice (n= 8 mice/group) after injection of
d the time spent licking the injected paw was measured at 5 min
) and phase II (15–45 min) between wild type (black column),
Univariate ANOVA with Bonferroni post-hoc analysis ##P < 0.01
Möser et al. Journal of Neuroinflammation  (2015) 12:100 Page 8 of 13the edema volume. Since no significant differences
were observed between the genotypes (Fig. 3a), it has
to be suggested that TBK1 does not directly influence
the inflammatory response in the paw. This assump-
tion was further supported by RT-PCR analyses of paw
tissue. Although TBK1 in wild type mice and the inflamma-
tory cytokines IL-1β, IL-6, and IFN-β1 in wild type, TBK1
−/−/TNFR−/− and TNFR−/− animals were strongly upregu-
lated after inflammatory stimulation, there were no signifi-
cant differences in the level of inflammatory cytokines
between the genotypes (Additional file 5: Figure S4).
Following injection of formalin, TNFR−/− as well as
TBK1−/−/TNFR−/− mice showed the typical biphasic noci-
ceptive behavior consisting of licking the injected paw.
The first phase (0–5 min) is due to chemical-fiber
stimulation of peripheral nociceptors [24]. After a gap
phase of ~10 min, the second phase lasts from 15–45 min
and corresponds to spinal sensitization. In comparison to
wild type mice, we already found an impaired nociceptive
response in mice with a deletion of TNFR. However,
TBK1−/−/TNFR−/− mice revealed a further decrease in
licking of the formalin-injected hind paw which was sig-
nificant in the second phase of the formalin assay as com-
pared to TNFR−/− mice (Fig. 3b) indicating that TBK1
makes an important contribution to the formalin-induced
C-fiber sensitization.
Regulation of NF-κB and IRF3 activity
Since NF-κB as well as IRF3 are important targets of TBK1,
we studied the regulation of these transcription factors in
the spinal cord of wild type, TBK1−/−/TNFR−/− as well as
TNFR−/− mice with and without formalin stimulation
(Fig. 4). NF-κB was significantly activated in nuclear ex-
tracts of the spinal cord of wild type animals after periph-



























Fig. 4 Regulation of NF-κB and IRF3 activation in the spinal cord. a p65 and b
factor ELISA. Nuclear extracts of the spinal cord of wild type, TNFR−/− and TBK
injection of formalin into the hind paws (n = 3 mice/group); bright colu
significant differences compared with untreated controlunaltered. In accordance with these data, IRF3 was nei-
ther affected in TBK1−/−/TNFR−/− nor in TNFR−/−
mice in this study. However, in contrast to the activa-
tion of NF-κB in wild type mice, we found no signifi-
cant effect of formalin in either TBK1−/−/TNFR−/− or
TNFR−/− mice indicating that the knock-out of TNFR
already inhibits NF-κB activation which covers possible ef-
fects of TBK1. Therefore, cell culture experiments with
RAW264.7 mouse macrophages, which were stably trans-
duced with TBK1 shRNA were additionally performed. In
comparison to control cells, which showed a significant
increase in phosphorylated NF-κB p65 (Ser536) 5 and
10 min after stimulation with LPS, knock-down of TBK1
by shRNA significantly decreased this phosphorylation by
about 50 % (Fig. 5a). These results are further supported
by experiments with primary bone marrow macrophages
(BMM) derived from TBK1−/−/TNFR−/− and TNFR−/−
mice. The LPS-induced increase of p65 (Ser536)-phos-
phorylation after 5 and 10 min stimulation in TNFR−/−
BMMs was significantly reduced in BMMs from TBK1−/−/
TNFR−/− mice (Fig. 5b) indicating that TBK1 is involved
in stimulus-dependent NF-κB activation which might at
least partially contribute to the effects observed in the
nociceptive animal models.
Regulation of potential TBK1 downstream targets
Further experiments were performed to clarify which
signal transduction pathways participate in the TBK1-
mediated nociception in the spinal cord. Since NF-κB
activation was only partially inhibited by downregulation
of TBK1 in RAW264.7 macrophages or BMMs from
TBK1−/−/TNFR−/− mice, we suggested that TBK1 down-
stream targets are not limited to the NF-κB cascade and
analyzed a panel of NF-κB dependent as well as inde-
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1−/−/TNFR−/− mice were prepared from control mice and mice 2 h after





































































Fig. 5 Regulation of NF-κB in RAW264.7 and primary bone marrow
macrophages. a Western blot showing serine 536 phosphorylation
of p65 in LPS-stimulated RAW264.7 macrophages stably transduced
with scrambled (black columns) or TBK1-specific shRNA (light grey
columns), (n = 4). The blots show a representative result; the diagram
shows the densitometric analysis of all experiments. b Western blot
showing serine 536 phosphorylation of p65 in LPS-stimulated BMMs
derived from TNFR−/− (dark grey columns) and TBK1−/−/TNFR−/− (light
grey columns) mice, (n = 4). The blots show a representative result, the
diagram shows the densitometric analysis of all experiments. Univariate
ANOVA with Bonferroni post-hoc analysis *P < 0.05 and ***P < 0.001
statistically significant differences compared with unstimulated
cells. Student’s t test #P < 0.05 and ##P < 0.01 significant mean difference
between scrambled shRNA and TBK1 shRNA or TNFR−/− and
TBK1−/−/TNFR−/− cells, respectively
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synthase (iNOS), and matrix metalloproteinase-9 (MMP-
9) showed the expected upregulation in the spinal cord
after peripheral formalin injection in wild type mice. iNOS
and MMP-9 induction were repressed in both TBK1−/−/
TNFR−/− and TNFR−/− mice in a similar manner, whereas
COX-2 regulation was normal in TNFR−/− mice and
significantly decreased in TBK1−/−/TNFR−/− animals.
For the NF-κB-independent genes c-fos and Akt1, a
formalin-induced increase in the spinal cord was ob-
served in wild type mice. The upregulation of Akt1 was
inhibited in both TBK1−/−/TNFR−/− and TNFR−/− mice,
whereas c-fos modulation was significantly repressed in
TBK1−/−/TNFR−/− animals but remained unaltered in
TNFR−/− mice (Fig. 6). These data indicate that COX-2
and c-fos strongly contribute to the TBK1-mediated
nociception. The role of COX-2 in TBK1 signaling in
nociception was further confirmed by experiments with
the COX-2 selective inhibitor celecoxib. While cele-
coxib treatment was able to further reduce the antino-
ciceptive effects of the TNFR-deletion in a significant
manner, the reduction in TBK1−/−/TNFR−/− mice was
only marginal thus further supporting the hypothesis
that COX-2 is a TBK1 downstream target (Additional
file 6: Figure S5). The strong regulation of c-fos prompted
us to investigate the regulation of MAP kinases which are
involved in the control of c-fos expression [25, 26] and
have been repeatedly associated with nociceptive re-
sponses [27–29]. As expected, we found a significant in-
crease in ERK 1/2, SAPK, and JNK activity in the spinal
cord of wild type mice after injection of formalin into the
paw as assessed by Western blot with phospho-specific
antibodies. The formalin-induced phosphorylation of ERK
1/2 and JNK was already inhibited in TNFR−/− mice, but
in TBK1−/−/TNFR−/− mice, we even found a decrease in
their phosphorylation to below baseline level. The increase
in p-SAPK levels was similar in wild type and TNFR−/−
mice but significantly inhibited in TBK1−/−/TNFR−/− mice
(Fig. 7). These results indicate that TBK1 contributes to c-
fos activation in inflammatory nociception by regulation
of MAP kinase activation. This is supported by cell culture
experiments with TBK1 depleted RAW264.7 macrophages
which showed a 50 % reduced c-fos activation in compari-
son to control cells in which activated c-fos was strongly
increased 60 min after LPS stimulation (Additional file 1:
Figure S6 B).
Discussion
The classical I-κB kinase complex consisting of the two
catalytical subunits IKKα and β and the regulatory sub-
unit IKKγ (NEMO) has been suggested to be an essen-
tial player in inflammatory NF-κB activation [30] and
also contributes to inflammatory nociception [10, 31]. In
a recent study, we found that the IKK-related IKKε is
time after formalin[[2h]
































Fig. 6 Regulation of NF-κB dependent and independent genes in the spinal cord. Quantitative RT-PCR (Taqman) of cyclooxygenase-2 (COX-2), inducible
NO-synthase (iNOS), matrix metalloproteinase-9 (MMP-9), c-fos, and Akt1 mRNA in the spinal cord of naïve mice and 2 h after formalin injection into a hind
paw. GAPDH-RNA was used as reference control gene (n= 4 mice/group) and each Taqman-PCR was performed twice in triplicate; black columns =wild
type; dark grey columns = TNFR−/−, light grey columns = TBK1−/−/TNFR−/−, Student’s t test *P< 0.05, **P< 0.01, and ***P< 0.001 in comparison to untreated
controls, #P< 0.05, ##P< 0.01 significant mean difference between TNFR−/− and TBK1−/−/TNFR−/− mice
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regulating NF-κB activity and the expression of NF-κB
dependent genes [13]. TBK1 constitutes another non-
canonical IKK which might form a complex with IKKε
and is involved in regulation of antiviral responses by
modulating IFN Type I and also in inflammatory pro-
cesses by regulating NF-κB signaling (reviewed in [7, 32,
33]). The aim of this study was to clarify whether TBK1
is also involved in inflammatory nociceptive processing.
We observed TBK1 expression in “pain-relevant” cells in
the spinal cord and the DRGs. After peripheral inflam-
matory nociceptive stimulation, TBK1 was upregulated
in the spinal cord but not in the DRGs indicating its
main role in the central nervous system. Effects in the
formalin model could be detected at earlier time points
compared to the zymosan A model which might reflect
the fact that the formalin model constitutes a more
acute inflammatory nociceptive model leading to early
effects while zymosan A-induced paw inflammation pro-
vides more information about persistent hyperalgesia
and later regulation [23]. TBK1 knock-out mice were
used to assess inflammatory hyperalgesia in the two dif-
ferent mouse models after confirming that similar ki-
nases such as IKKα, β, and ε do not compensate for the
TBK1 deletion. Due to embryonic lethality of complete
TBK1 knock-out mice as a result of liver degeneration
and apoptosis [16, 34], the TBK1−/− mice had to be bred
under a TNFα-receptor knock-out and were compared
to TNF-α receptor knock-out mice (TNFR−/−) as con-
trols. A knock-out of TNFR in mice has already been re-
peatedly associated with reduced nociceptive responses
in models of inflammatory, cancer, and neuropathic pain
[35–37] and might thus cover antinociceptive effectsmediated by TBK1 knock-down. Accordingly, we showed
that the TNFR knock-out already ameliorates nociception
in the formalin test and in the zymosan A-induced paw
inflammation. Nevertheless, in TBK1/TNFR double-knock-
out mice, this effect was significantly enhanced indicating
that TBK1 contributes to inflammatory hyperalgesia.
These results are in accordance with studies showing anti-
inflammatory effects of TBK1 inhibition in fibroblast-like
synoviocytes by reducing the expression of the proinflam-
matory protein IP-10 [17]. Furthermore, TBK1 is involved
in the inflammatory response in obesity and hypertension
and contributes to phosphorylation of the insulin receptor
thus impairing its function and supporting insulin resist-
ance [18]. Treatment of obese mice with the TBK1/IKKε
inhibitor amlexanox led to weight loss and improved insu-
lin sensitivity by elevation of energy expenditure [38, 39],
which further confirms that TBK1 contributes to proin-
flammatory reactions. Our concern was to investigate
whether TBK1 effects in nociception are mediated via NF-
κB signaling possibly in concert with IKKε or via other
pathways. In a recent study, we used BX795 as a pharma-
cological inhibitor of IKKε and TBK1 and showed that the
combined inhibition of both kinases led to a stronger re-
duction of the noxious response in comparison to single
IKKε knock-out [13]. Together, with the results of this
study, it seems that inhibition of both kinases by BX795
leads to an addition of the effects of IKKε- and TBK1-
mediated analgesia which might be due to synergistic
modulation of the same target genes or to regulation of
different targets, respectively. For IKKε, we showed that a
complete inhibition of NF-κB p65 phosphorylation at Ser
536 was responsible for inhibition of NF-κB dependent
















































































Fig. 7 Regulation of MAPK activity in the spinal cord of wild type, TNFR−/− and TBK1−/−/TNFR−/− mice. Western blots showing the activation of
SAPK (a), JNK (b), ERK1 (c), and ERK 2 (d) in different genotypes as assessed by Western blot analysis with phospho-specific antibodies. The blots
were normalized to the respective total protein levels and additionally against the loading control HSP90 or β-actin. The blots show a representative
result, the diagram shows the densitometric analysis of three independent experiments (n= 3 mice/group); dark columns = control; bright columns = 30 min
formalin. Student’s t test *P < 0.05 and **P < 0.01 significant mean difference between untreated and formalin–injected mice. #P < 0.05 and
##P < 0.01 significant mean difference between TNFR−/− and TBK1−/−/TNFR−/− mice
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sults of this study revealed that a knock-down of TBK1
also inhibits NF-κB activation by decreasing phosphoryl-
ation of p65 Ser536 but to a lesser extent than that shown
for IKKε inhibition. From these data and published studies
which hint towards divergent functional roles for TBK1
and IKKε [5, 6], we postulated that TBK1 might affect
other target genes in addition. Indeed, we found that the
NF-κB-independent marker of neural activity, c-fos, was
also differentially regulated in TBK1 knock-out mice in
comparison to TNFR−/− and wild type mice in association
with a decreased activation of the MAP kinases ERK1/2
and SAPK/JNK. These MAPKs have been frequently asso-
ciated with nociceptive responses [27–29] and inhibition of
their activation might contribute to antinociceptive effects inTBK1 knock-out mice. A relationship between TBK1 and
MAPKs has already been found in a study with TBK1−/−
mouse embryonic fibroblasts (MEFs) which showed reduced
TNFα-induced MAPK activation in comparison to TBK1+/+
cells [40]. In contrast, TBK1 was not involved in MAPK
activation stimulated by double stranded DNA [41] or TLR-
3 activation [42]. A recent study has further shown that NF-
κB activation is capable of participation in c-fos induction,
but only in concert with ERK-mediated fos induction [43], a
mechanism which might also have contributed to TBK1 sig-
naling in this study and supports the increase in c-fos. IRF3,
which has been frequently described as a prominent TBK1
target, seems to play only a minor role in nociception, since
it was not affected by nociceptive stimulation or by deletion
of TBK1.
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This study shows that TBK1, similar to IKKε, is involved
in inflammatory nociceptive processing in the spinal
cord and might therefore constitute a promising target
for pharmacological intervention in pain. Our data indi-
cate that, on the one hand, TBK1 and IKKε work to-
gether in a complex to inhibit NF-κB signal transduction
while, on the other hand, TBK1 additionally exerts
IKKε-independent actions by the so far undescribed
in vivo regulation of MAP kinases and c-fos. Neverthe-
less, the embryonic lethality of a complete TBK1 knock-
out raises concerns that inhibition of TBK1 in humans
would be associated with severe unwanted side effects.
A possible solution to this problem might be tissue-
specific modulation of TBK1 or drugs with combined
IKKε/TBK1 inhibitory potency which can be adminis-
tered at low doses.
Additional information
Additional methods and figure legends are provided in
Additional file 7.
Additional files
Additional file 1: Figure S6. Stable downregulation of TBK1 is
associated with decreased LPS-induced c-fos activity. (A) Western blot
showing TBK expression in RAW264.7 macrophages stably transduced
with scrambled or TBK1-specific shRNA during the time course of LPS-
incubation. The blots show a representative result, the diagram shows
the densitometric analysis of four independent experiments. (B) c-fos
transcription factor activity in nuclear extracts of RAW264.7 cells stably
transduced with scrambled shRNA or TBK1 shRNA, respectively, as assessed by
TransAM transcription factor ELISA (n= 3); black columns = scrambled shRNA;
light grey columns = TBK1 shRNA, Univariate ANOVA with Bonferroni post-hoc
analysis *P < 0.05 and ***P < 0.001 in comparison to untreated control,
#P < 0.05, significant mean difference between scrambled shRNA and
TBK1 shRNA.
Additional file 2: Figure S1. Antibody specificity. Western Blot analysis
(A) and immunofluorescence ((B): dorsal spinal cord, (C): DRG) of TBK1 in
different mouse genotypes to confirm specificity of the antibody. Scale
Bar: 10 μm.
Additional file 3: Figure S2. Regulation of TBK1 in primary immune
cells after inflammatory stimulation. Regulation of TBK1 mRNA in primary
astrocytes (A) and microglia (B) after stimulation with a cytokine mix (TNF-α,
5 ng/ml; IL-1β, 1 ng/ml; LPS, 1 μg/ml) for 6 and 24 h, respectively, analyzed by
quantitative RT-PCR. n= 3 independent incubations/cell type. Univariate
ANOVA with Bonferroni post-hoc analysis * P< 0.05, and *** P< 0.001.
Additional file 4: Figure S3. TBK1expression and regulation in the
dorsal root ganglia. (A) Representative co-immunofluorescence showing
TBK1 expression in the dorsal root ganglia (one of 3 independent experiment,
n = 3 mice/group) in combination with cell markers of non-myelinated
nociceptive afferents (IB4) (A) and large myelinated non-nociceptive
neurons (NF200) (B), respectively. TBK1 was stained with Cy-3 (red), cell
markers with Alexa Fluor 488 (green). The images show (from left to
right side): TBK1 alone, cell marker alone, and merged (representative
result from 3 independent experiments). Scale Bar: 20 μm. (C, D) Time
course of the TBK1 mRNA expression in the dorsal root ganglia after
peripheral injection of zymosan A (C) and formalin (D), respectively, (n= 3
mice/group).
Additional file 5: Figure S4. Regulation of TBK1 and inflammatory
cytokines in the paw. (A) TBK1 mRNA expression in the contra- and ipsilateralpaws of wild type mice 48 h after zymosan injection. Student’s t test
***P < 0.001 significant mean difference between contra- and ipsilateral paws
(n= 3 mice/group). (B-D) Regulation of inflammatory cytokines (B: IL-1β, C: IL-6,
D: IFN-β1) in the contra- and ipsilateral paws of wild type (black columns),
TNFR−/−(dark grey columns) and TBK1−/−/TNFR−/−mice (light grey columns)
48 h after zymosan injection. Univariate ANOVA with Bonferroni
post-hoc analysis, ***P < 0.001 significant mean difference compared
to contralateral paw (n = 3 mice/group).
Additional file 6: Figure S5. Effects of celecoxib on zymosan-induced
hyperalgesia in mice with different genotypes. Time course of mechanical
hyperalgesia in wild type (A), TNFR−/−mice (B) and TBK1−/−/TNFR−/−mice
(C) with and without administration of celecoxib (10 mg/kg BW, p.o.)
30 min prior to zymosan A injection. The diagram shows the delta paw
withdrawal latencies (ΔPWL) in response to mechanical stimulation as
assessed with a Dynamic Plantar Aesthesiometer (n = 6 mice/group
(D)). Comparison of the area under the paw withdrawal latency versus
time curve between wild type (black column), TNFR−/−(dark grey column)
and TBK1−/−/TNFR−/−(light grey column) mice 3 to 7 h after zymosan A
injection. Univariate ANOVA with Bonferroni post-hoc analysis, *P < 0.05
significant mean difference between celecoxib/zymosan treated groups and
zymosan treated controls. #P<0.05 significant mean difference between the
genotypes.
Additional file 7: Additional methods and figure legends.
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